INDIGO - DIOPSYS

Pathology: Non-Proliferative Diabetic Retinopathy (NPDR)

Description: Quantitative evaluation of retinal function in eyes with diabetic retinopathy treated with anti-VEGF (ERG)

Study Objectives: Primary - To assess the ability of Flicker ERG to detect changes in retinal function following anti-VEGF treatment in patients with diabetic retinopathy. Secondary - To investigate the correlation between changes in retina function with the severity of diabetic retinopathy.

Principal Investigator: Dr. Blinder

Status: Open Enrollment


MERLIN

Pathology: Wet Age-Related Macular Degeneraton (AMD)

Description: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Study Objectives: The purpose of this study is to compare safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those nAMD patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.

Principal Investigator: Dr. Blinder

Status: Open Enrollment


NORSE 2 - ONS-5010-002

Pathology: Wet Age-Related Macular Degeneration (AMD)

Description: A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration

Study Objectives: This study will assess the efficacy and safety of intravitreal injections of ONS-5010 administered monthly compared with ranibizumab 0.5 mg injections administered for 3 doses and then quarterly in subjects with primary or recurrent CNV with or without a classic CNV component secondary to age-related macular degeneration.

Principal Investigator: Dr. Durrani

Status: Open Enrollment